Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
Dr. Zouzoulas discusses key patient considerations to consider when deciding on an intravenous or subcutaneous biologic.
Video content above is prompted by the following questions:
- How do you position IV and subcutaneous biologics in your treatment algorithms? Which patients are ideal for IV and which patients are ideal for subQ?
- Patients have more frequent contact with physicians with IV route of administration vs. subQ. Do you think this fosters better relationships and increases adherence?
K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies
October 7th 2024Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
